145.52
Overview
News
Price History
Option Chain
Financials
Why BDX Down?
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $145.52, with a volume of 1.76M.
It is down -0.49% in the last 24 hours and up +1.43% over the past month.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
See More
Previous Close:
$146.24
Open:
$146.6
24h Volume:
1.76M
Relative Volume:
0.65
Market Cap:
$40.10B
Revenue:
$21.37B
Net Income/Loss:
$1.41B
P/E Ratio:
36.90
EPS:
3.9437
Net Cash Flow:
$3.07B
1W Performance:
-2.98%
1M Performance:
+1.43%
6M Performance:
-27.27%
1Y Performance:
-15.50%
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
BDX
Becton Dickinson Co
|
145.52 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
|
ISRG
Intuitive Surgical Inc
|
416.55 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
|
ALC
Alcon Inc
|
66.29 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
|
MDLN
Medline Inc
|
37.33 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
|
RMD
Resmed Inc
|
192.74 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Resumed | Goldman | Neutral |
| Feb-10-26 | Resumed | Barclays | Overweight |
| Feb-03-26 | Resumed | Citigroup | Buy |
| Sep-25-25 | Initiated | RBC Capital Mkts | Sector Perform |
| May-22-25 | Downgrade | Citigroup | Buy → Neutral |
| May-02-25 | Downgrade | Goldman | Buy → Neutral |
| May-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-01-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-18-22 | Resumed | Raymond James | Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-01-20 | Resumed | Goldman | Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
| Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-07-18 | Initiated | Deutsche Bank | Buy |
| Oct-16-18 | Initiated | Barclays | Equal Weight |
| Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Jan-19-18 | Resumed | BofA/Merrill | Buy |
| Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
| Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
BofA Adjusts Price Target on Becton, Dickinson and Company to $170 From $177 - Moomoo
Becton Dickinson and Co Stock (US0758871091): Valuation Check As Shares Lag 2026 Highs - AD HOC NEWS
Is Becton, Dickinson and Company (BDX) A Good Stock To Buy Now? - Yahoo Finance
Deals tracker: Medtronic buys Scientia Vascular for $550M - Modern Healthcare
Becton Dickinson & Co Stock (US0758871091): Stock in focus after a quiet news day - AD HOC NEWS
BofA Securities Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Cuts Target Price to $170 - Moomoo
Becton Dickinson EVP Michael Garrison sells $166,628 in stock - Investing.com UK
Tranche Update on Becton, Dickinson and Company's Equity Buyback Plan announced on January 27, 2026. - marketscreener.com
Becton Dickinson & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Becton Dickinson & Co (BDX) Revenue BreakdownMain Composition - Moomoo
Becton, Dickinson and Company: - marketscreener.com
Becton, Dickinson and Company (BDX) Stock Analysis: Unpacking a 19.89% Potential Upside - DirectorsTalk Interviews
Jim Cramer on Becton, Dickinson: “I Think You Buy Some and Then You Wait” - insidermonkey.com
Becton Dickinson earnings loom as investors eye post-divestiture growth By Investing.com - Investing.com
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Is It Smart To Buy Becton, Dickinson and Company (NYSE:BDX) Before It Goes Ex-Dividend? - Yahoo Finance
Becton Dickinson & Co. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch
June 3, 2026Polen Thomas E Jr - Becton Dickinson
Becton Dickinson chairman, CEO Thomas E. Polen Jr. sells $404k in shares - Investing.com UK
Wound Irrigation Systems Market to Skyrocket USD 430.05 Million by 2035 as Chronic Wound Cases and Surgical Volumes Rise Worldwide | SNS Insider - GlobeNewswire Inc.
Becton Dickinson & Co Insider Sold Shares Worth $404,511, According to a Recent SEC Filing - marketscreener.com
June 2, 2026Menziuso Peter3 - Becton Dickinson
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton Dickinson & Co stock (US0758871091): Norges Bank stake highlights interest after recent earni - AD HOC NEWS
Becton, Dickinson And Company (BDX) Stock Analysis: Exploring A 23% Upside Potential - DirectorsTalk Interviews
TD Cowen Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $163 - 富途牛牛
Becton Dickinson resumes U.S. shipments of ChloraPrep after additional testing - TradingView
Here’s Hinde Group’s Updates on Becton, Dickinson and Company (BDX) - Insider Monkey
Piper Sandler Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Raises Target Price to $161 - Moomoo
Insider Sell: Michael Feld Sells Shares of Becton Dickinson & Co (BDX) - GuruFocus
Becton Dickinson EVP Michael Feld sells $11,051 in stock - Investing.com UK
Becton Dickinson EVP Michael Feld sells $11,051 in stock By Investing.com - Investing.com UK
Goldman Sachs Adjusts PT on Becton, Dickinson and Co. to $150 From $156, Maintains Neutral Rating - Moomoo
Becton, Dickinson And Company (BDX): Evaluating Growth Potential With A 24% Upside - DirectorsTalk Interviews
Elyra Kidney Stone Laser Launch Tests Becton Dickinson Execution Story - simplywall.st
Becton, Dickinson & Co. Faces Valuation Shift Amid Declining Stock Returns and High Debt - Markets Mojo
BD Delivers Kidney Stone Care for Urology Teams with the Elyra Thulium Fiber Laser System - Finviz
New BD laser targets smoother, quieter kidney stone care procedures - Stock Titan
Becton Dickinson and Co stock (US0758871091): new €600 million notes and recent loss raise questio - AD HOC NEWS
Becton, Dickinson and Company (BDX) Announces €600 Million Notes Offering - GuruFocus
Becton Dickinson Euro Finance Issues €600 Million 3.855% Notes Due 2033 Guaranteed by BD - Minichart
Becton Dickinson subsidiary issues €600 million in 3.855% notes due 2033 - Investing.com Canada
Becton Dickinson Issues €600 Million 3.855% Notes Due 2033 to Refinance 2026 Debt - TradingView
A Look at Becton Dickinson & Co (BDX) After 3.2% Gain -- GF Value $194.45 vs Price $146.95 - GuruFocus
Nebulizers - GlobeNewswire Inc.
Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock? - Barchart.com
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):